Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04744116|
Recruitment Status : Recruiting
First Posted : February 8, 2021
Last Update Posted : February 15, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Hematopoietic and Lymphoid Cell Neoplasm Steroid Refractory Graft Versus Host Disease||Other: Cellular Therapy Drug: Ruxolitinib||Early Phase 1|
I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Pilot Study of Two Doses of Cord Blood Tissue-Derived Mesenchymal Stromal Cells Combined With Ruxolitinib Versus Ruxolitinib Alone for Therapy of Steroid-Refractory Acute Graft Versus Host Disease|
|Actual Study Start Date :||February 17, 2021|
|Estimated Primary Completion Date :||March 15, 2024|
|Estimated Study Completion Date :||March 15, 2024|
Active Comparator: Arm 1 (ruxolitinib)
Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
Experimental: Arm 2 (ruxolitinib, lower dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
Other: Cellular Therapy
Given ds-MSCs IV
Other Name: Cell Therapy
Experimental: Arm 3 (ruxolitinib, higher dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
Other: Cellular Therapy
Given ds-MSCs IV
Other Name: Cell Therapy
- Death from any cause [ Time Frame: Within 28 days from the start of active study treatment ]
- Response [ Time Frame: At day 28 from start of therapy on study ]Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed.
- Incidence of adverse events [ Time Frame: Within 28 days from the start of active study treatment ]
- Graft versus host disease status [ Time Frame: At days 7, 14, 21 and 28 post treatment ]Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD).
- Proportion of response [ Time Frame: At days 7, 14, 21 and 28 post treatment ]Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies.
- Time to complete response [ Time Frame: Up to 6 months ]Will be estimated by the method of Kaplan and Meier.
- Time to very good partial response [ Time Frame: Up to 6 months ]Will be estimated by the method of Kaplan and Meier.
- Time to partial response [ Time Frame: Up to 6 months ]Will be estimated by the method of Kaplan and Meier.
- Incidence of complete response for each organ [ Time Frame: Up to 6 months ]
- Incidence of very good partial response for each organ [ Time Frame: Up to 6 months ]
- Incidence of partial response for each organ [ Time Frame: Up to 6 months ]
- Durability of organ response [ Time Frame: Up to 6 months ]
- Cumulative incidence of non-relapse mortality (NRM) [ Time Frame: At 6 months post treatment ]
- Cumulative incidence of relapse/progression of the primary disease [ Time Frame: At 6 months ]
- Overall survival [ Time Frame: From enrollment to death from any cause, assessed at 6 months ]
- Disease-free survival [ Time Frame: From enrollment to death from any cause or relapse/progression of the primary disease, assessed at 6 months ]
- Graft versus host disease-free survival [ Time Frame: At 6 months ]Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint
- Incidence of chronic graft versus host disease [ Time Frame: At 6 months after first mesenchymal stromal cells (MSC) infusion ]Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months.
- Incidence of systemic infections [ Time Frame: 28 days after last study drug ]The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity.
- Incidence of toxicities [ Time Frame: Up to 28 days after completing last MSC infusion study drug ]The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described.
- Incidence of any grade cytokine release [ Time Frame: Up to 28 days after completing last MSC infusion study drug ]
- Incidence of any infusional toxicity [ Time Frame: Within 24 hours of each cord blood-MSC infusion ]
- Cytokine biomarker analysis (optional) [ Time Frame: Up to 6 months ]Will use cytokine biomarker assays to predict response to therapy.
- Fecal samples analysis (optional) [ Time Frame: Up to 6 months ]Will use fecal samples to assess microbiome and potential predictor for response to therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years to 80 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients between the ages of 12 years and 80 years (inclusive).
- Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Patients must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
- Estimated creatinine clearance ≥ 30 mL/min
- Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
- Patients who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
- Patient (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.
- De novo chronic GVHD
- Isolated acute GVHD of skin
- Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
- Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
- Patients with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Patient with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
- Patient with known allergy to bovine or porcine products.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04744116
|Contact: Partow Kebriaei, MDfirstname.lastname@example.org|
|United States, Texas|
|M D Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Partow Kebriaei, MD 713-745-0663 email@example.com|
|Principal Investigator: Partow Kebriaei, MD|
|Principal Investigator:||Partow Kebriaei, MD||M.D. Anderson Cancer Center|
|Responsible Party:||M.D. Anderson Cancer Center|
|Other Study ID Numbers:||
NCI-2020-13889 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2019-1122 ( Other Identifier: M D Anderson Cancer Center )
P01CA148600 ( U.S. NIH Grant/Contract )
|First Posted:||February 8, 2021 Key Record Dates|
|Last Update Posted:||February 15, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Graft vs Host Disease
Immune System Diseases
Janus Kinase Inhibitors
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action